187660 — Penetrium Bioscience Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual income statement for Penetrium Bioscience, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	13,978	14,883	13,790	9,745	9,273
Cost of Revenue
Gross Profit	7,236	4,365	3,217	101	33.6
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	11,887	15,637	15,701	25,724	16,701
Operating Profit	2,091	-755	-1,911	-15,979	-7,428
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,170	76.6	-1,776	-18,232	-14,713
Provision for Income Taxes
Net Income After Taxes	1,727	-58.9	-1,831	-18,094	-14,830
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	1,923	267	-2,970	-20,096	-14,830
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	1,923	65.4	-2,970	-20,096	-14,830
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	48.2	1.45	-43.1	-427	-314
Dividends per Share